Choosing Wisely: A Systematic Review of Terlipressin Versus Octreotide for Variceal Bleeding.

High pressure in the portal circulation is a key indicator of advanced liver disease. It has many harmful effects on patients with cirrhosis, such as promoting the growth of dilated esophageal vessels. As portal pressure rises, it creates serious risks for life-threatening bleeding problems from variceal sources, which leads to higher mortality and worse patient outcomes. A multidisciplinary approach that includes pharmacologic and endoscopic procedures and radiological techniques is necessary to treat variceal hemorrhage effectively. There are typically three main components to clinical management: primary prophylaxis, which is the initial step in preventing disease; secondary prophylaxis, which is the second step; and acute hemorrhage management, which is the third step. The goal of both primary and secondary prophylactic measures is to stop variceal bleeding episodes from happening. Acute variceal hemorrhage is a severe medical condition that needs immediate treatment to stop the bleeding and prevent it from happening again. Vasoactive drugs are the primary treatment for all patients with suspected variceal bleeding. They are safe and simple to give, and they are part of standard treatment protocols. When bleeding continues during an endoscopic procedure, there is strong evidence that vasoactive drugs should be given right away, preferably before the diagnostic endoscopy. There is a lack of direct comparative studies in the current literature that look at the relative therapeutic benefits of vasoactive drugs when used as adjunctive therapies with endoscopic interventions for managing variceal bleeding. The goal of this systematic review was to look at and compare the safety and effectiveness of various vasoactive drugs as supportive treatments for patients with esophageal variceal hemorrhage who were also receiving endoscopic therapy. We used a search strategy that included several electronic databases, such as PubMed, PubMed Central, ScienceDirect, and Google Scholar, to find studies that investigated how well these two drugs worked in treating active variceal bleeding outcomes. The review included a range of study types, such as meta-analyses, observational studies, case-control studies, systematic reviews, narrative reviews, and randomized controlled trials (RCTs). A total of 22,422 participants were included in the final analysis of 14 studies, including two RCTs, two observational studies, seven meta-analyses, and three narrative reviews. The results revealed that various vasoactive drugs had similar therapeutic effects on controlling bleeding, length of hospital stay, death rates, and adverse event profiles when used as adjunctive therapies. The research demonstrated that vasoactive medication treatment results in improved control of bleeding and shorter hospital stays. It also led to lower rates of immediate death from all causes and fewer blood product requirements. Many studies comparing these drugs found that they all worked similarly in clinical settings. Further research is therefore needed, such as high-quality randomized controlled trials, to strengthen these conclusions.